Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Antithrombin III - Grifols

X
Drug Profile

Antithrombin III - Grifols

Alternative Names: AT-III; ATIII - Grifols; Thrombate; Thrombate III

Latest Information Update: 16 Mar 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Grifols
  • Developer Endpoint Health; Grifols
  • Class Alpha globulins; Anti-infectives; Anticoagulants; Antithrombins; Antithrombotics
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Antithrombin III deficiency
  • Research Sepsis

Most Recent Events

  • 24 Feb 2022 Endpoint Health in-licenses antithrombin III from Grifols
  • 24 Feb 2022 Early research in Sepsis in USA (unspecified route)
  • 24 Feb 2022 Endpoint Health plans to file an IND application with the US FDA for phase II trial in Sepsis in 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top